Show items per page
Elements: 3
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Huls, Gerwin; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; ... Ossenkoppele, Gert J 2020
add to browser selection
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; van Norden, Yvette; ... Ossenkoppele, Gert J 2017
add to browser selection
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study Terwijn, Monique; van Putten, Wim L J; Kelder, Angèle; van der Velden, Vincent H J; ... Schuurhuis, Gerrit J 2013